Targeting protein degradation to treat advanced childhood tumors
PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors
This study is working on new and better treatments for kids with tough-to-treat brain tumors, using cutting-edge techniques to target the specific features of these cancers, so that young patients can have more effective options to help them fight their illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prinses Maxima Voor Kinderoncologie, Bv NIH-funded |
| Lab location | 1 site (Utrecht, Netherlands) |
| Project ID | NIH-11043561 on NIH RePORTER |
What this research studies
This research focuses on developing innovative treatments for children with advanced solid tumors, particularly brain tumors, which have seen stagnant survival rates. By utilizing advanced techniques like CRISPR-Cas9 and targeted protein degradation, the team aims to specifically target the unique biological characteristics of these tumors. The approach involves a collaborative effort from experts in various fields to create effective therapies that can overcome the limitations of traditional treatments. Patients may benefit from new, more effective treatment options that directly address the underlying causes of their cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with advanced solid tumors, particularly those resistant to current treatment options.
Not a fit: Patients with tumors that are not classified as solid or those outside the age range of 0-11 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for childhood cancers, improving survival rates and quality of life for young patients.
How similar studies have performed: Other research has shown promise in targeting previously undruggable proteins in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Utrecht, Netherlands
- Prinses Maxima Voor Kinderoncologie, Bv — Utrecht, Netherlands (Active)
Researchers
- Principal investigator: Wienke, Judith — Prinses Maxima Voor Kinderoncologie, Bv
- Study coordinator: Wienke, Judith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.